Description: OncoTrack, an international consortium of over 60 scientists, managed by Bayer AG and the Max Planck Institute for Molecular Genetics, has launched one of Europes largest collaborative academic-industry research projects to develop and assess novel approaches for identification of new markers for colon cancer.
science (6270) eu (2328) oncology (605) genetics (476) fp7 (52) biomarker (44) imi (43) research project (30) molecular genetics (7) imi ju (1)
OncoTrack received research funding from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115234 resources of which are composed of financial contribution from the European Unions Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution.
The funding period for the project ended on December 31st, 2016.
OncoTrack, Methods for systematic next generation oncology biomarker development , is an international consortium of over 100 scientists, that has launched one of Europes largest collaborative academic-industry research projects to develop and assess novel approaches for identification of new markers for colon cancer. This unique six year project brings together top scientists from European academic institutions offering a wide range of expertise, and partners them with pharmaceutical companies.